Found: 7
Select item for more details and to access through your institution.
Intravital assessment of myelin molecular order with polarimetric multiphoton microscopy.
- Published in:
- Scientific Reports, 2016, p. 31685, doi. 10.1038/srep31685
- By:
- Publication type:
- Article
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
- Published in:
- CNS Drugs, 2023, v. 37, n. 3, p. 275, doi. 10.1007/s40263-022-00982-6
- By:
- Publication type:
- Article
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
(QOL11) Natalizumab Is Associated with Improvement in Cognitive Processing Speed and Health-Related Quality of Life: STRIVE 4-Year Results.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 65
- By:
- Publication type:
- Article
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 3, p. 833, doi. 10.1007/s40120-023-00461-0
- By:
- Publication type:
- Article
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 7, p. 3724, doi. 10.1007/s12325-021-01722-w
- By:
- Publication type:
- Article